Ashutosh Wechalekar

27.0k total citations · 2 hit papers
267 papers, 10.5k citations indexed

About

Ashutosh Wechalekar is a scholar working on Molecular Biology, Nephrology and Genetics. According to data from OpenAlex, Ashutosh Wechalekar has authored 267 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 248 papers in Molecular Biology, 83 papers in Nephrology and 63 papers in Genetics. Recurrent topics in Ashutosh Wechalekar's work include Amyloidosis: Diagnosis, Treatment, Outcomes (240 papers), Parathyroid Disorders and Treatments (73 papers) and Neuroendocrine Tumor Research Advances (40 papers). Ashutosh Wechalekar is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (240 papers), Parathyroid Disorders and Treatments (73 papers) and Neuroendocrine Tumor Research Advances (40 papers). Ashutosh Wechalekar collaborates with scholars based in United Kingdom, United States and Italy. Ashutosh Wechalekar's co-authors include Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Carol Whelan, Giampaolo Merlini, Giovanni Palladini, Janet A. Gilbertson, Dorota Rowczenio, Marianna Fontana and Simon Gibbs and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

Ashutosh Wechalekar

248 papers receiving 10.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

2012 625 citations Giovanni Palladini, Morie A. Gertz et al. profile →
Systemic amyloidosis

2015 621 citations Ashutosh Wechalekar, Julian D. Gillmore et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ashutosh Wechalekar	9.3k	3.2k	2.3k	2.2k	1.6k	267	10.5k
Vaishali Sanchorawala	7.7k 0.8×	2.1k 0.7×	2.4k 1.1×	1.7k 0.8×	1.7k 1.0×	281	8.3k
Stefan Schönland	5.9k 0.6×	1.4k 0.4×	1.6k 0.7×	1.5k 0.7×	1.1k 0.7×	222	7.2k
Raymond L. Comenzo	6.7k 0.7×	1.4k 0.4×	2.1k 0.9×	2.4k 1.1×	1.2k 0.7×	230	8.3k
Steven R. Zeldenrust	7.7k 0.8×	1.3k 0.4×	1.6k 0.7×	3.7k 1.7×	796 0.5×	165	9.9k
Janet A. Gilbertson	3.9k 0.4×	1.6k 0.5×	361 0.2×	1.1k 0.5×	497 0.3×	96	4.7k
Taxiarchis Kourelis	1.7k 0.2×	199 0.1×	612 0.3×	813 0.4×	311 0.2×	215	2.7k
Stefan Knop	1.9k 0.2×	186 0.1×	396 0.2×	2.1k 0.9×	207 0.1×	152	4.4k
Suzanne Lentzsch	4.5k 0.5×	117 0.0×	920 0.4×	3.4k 1.5×	201 0.1×	227	7.2k
Jeffrey A. Zonder	2.9k 0.3×	162 0.1×	661 0.3×	1.9k 0.9×	192 0.1×	194	4.6k
Bethan Psaila	1.9k 0.2×	139 0.0×	677 0.3×	1.5k 0.7×	110 0.1×	61	5.5k

Countries citing papers authored by Ashutosh Wechalekar

Since Specialization

Citations

This map shows the geographic impact of Ashutosh Wechalekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashutosh Wechalekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashutosh Wechalekar more than expected).

Fields of papers citing papers by Ashutosh Wechalekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashutosh Wechalekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashutosh Wechalekar. The network helps show where Ashutosh Wechalekar may publish in the future.

Co-authorship network of co-authors of Ashutosh Wechalekar

This figure shows the co-authorship network connecting the top 25 collaborators of Ashutosh Wechalekar. A scholar is included among the top collaborators of Ashutosh Wechalekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashutosh Wechalekar. Ashutosh Wechalekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khwaja, Jahanzaib, Sriram Ravichandran, Oliver C. Cohen, et al.. (2025). Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis. British Journal of Haematology. 206(4). 1141–1148. 1 indexed citations

Khwaja, Jahanzaib, Sriram Ravichandran, Oliver C. Cohen, et al.. (2024). Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System. Blood. 144(Supplement 1). 890–890.

Khwaja, Jahanzaib, Sriram Ravichandran, Darren Foard, et al.. (2024). Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis. Blood. 144(Supplement 1). 4684–4684.

Patel, Rishi, Ana Martinez–Naharro, Yousuf Razvi, et al.. (2024). 5 Cardiovascular magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy – a study of natural history and treatment repsonse. Abstracts. A2.1–A2. 1 indexed citations

Khwaja, Jahanzaib, Josephine M. I. Vos, Arjan J. Kwakernaak, et al.. (2023). Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia. British Journal of Haematology. 204(1). 177–185. 9 indexed citations

Cohen, Oliver, Regina Rendas‐Baum, Kristen McCausland, et al.. (2023). Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis. British Journal of Haematology. 201(3). 422–431. 3 indexed citations

Khwaja, Jahanzaib, Sriram Ravichandran, Oliver Cohen, et al.. (2023). Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients. Blood. 142(Supplement 1). 537–537. 5 indexed citations

Sanchorawala, Vaishali, Ashutosh Wechalekar, Efstathios Kastritis, et al.. (2023). Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis. Blood. 142(Supplement 1). 3409–3409. 2 indexed citations

Ioannou, Adam, Yousuf Razvi, Aldostefano Porcari, et al.. (2023). Tracking multi-organ treatment response in systemic AL amyloidosis with cardiac magnetic resonance derived extracellular volume mapping. European Heart Journal - Cardiovascular Imaging. 24(Supplement_1). 1 indexed citations

10.

Wechalekar, Ashutosh, María Teresa Cibeira, Simon Gibbs, et al.. (2022). Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 30(1). 3–17. 46 indexed citations

11.

Quarta, Candida Cristina, David F. Hutt, Richa Manwani, et al.. (2021). 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging. 22(11). 1304–1311. 42 indexed citations

12.

Law, Steven, Aviva Petrie, Liza Chacko, et al.. (2021). Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart. 108(6). 474–478. 20 indexed citations

13.

Cohen, Oliver C., Faye Sharpley, Julian D. Gillmore, et al.. (2020). Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis. British Journal of Haematology. 189(4). 643–649. 28 indexed citations

14.

Manwani, Richa, Shameem Mahmood, Sajitha Sachchithanantham, et al.. (2019). Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. British Journal of Haematology. 187(5). 638–641. 36 indexed citations

15.

Rezk, Tamer, Helen J. Lachmann, Marianna Fontana, et al.. (2019). Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. British Journal of Haematology. 186(3). 460–470. 15 indexed citations

16.

Manwani, Richa, David Wrench, Ashutosh Wechalekar, & Helen J. Lachmann. (2018). Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma. British Journal of Haematology. 182(5). 619–619. 2 indexed citations

17.

Rezk, Tamer, Andrew Davenport, Helen J. Lachmann, et al.. (2018). Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis. British Journal of Haematology. 185(5). 977–980. 4 indexed citations

18.

Sharpley, Faye, Richa Manwani, Shameem Mahmood, et al.. (2018). Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. British Journal of Haematology. 183(4). 557–563. 12 indexed citations

19.

Rezk, Tamer, Carol Whelan, Helen J. Lachmann, et al.. (2017). Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis. British Journal of Haematology. 182(1). 145–148. 17 indexed citations

20.

Venner, Christopher P., Thirusha Lane, Darren Foard, et al.. (2012). Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 119(19). 4387–4390. 197 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact